Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
pegfilgrastim
Amgen Europe B.V.
L03AA13
pegfilgrastim
Immunostimulants,
Neutropenia
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)
Revision: 3
Withdrawn
2015-04-13
25 B. PACKAGE LEAFLET Medicinal product no longer authorised 26 PACKAGE LEAFLET: INFORMATION FOR THE USER RISTEMPA 6 MG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE pegfilgrastim This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ristempa is and what it is used for 2. What you need to know before you use Ristempa 3. How to use Ristempa 4. Possible side effects 5. How to store Ristempa 6. Contents of the pack and other information 1. WHAT RISTEMPA IS AND WHAT IT IS USED FOR Ristempa contains the active substance pegfilgrastim. Pegfilgrastim is a protein produced by biotechnology in bacteria called _E. coli_ . It belongs to a group of proteins called cytokines, and is very similar to a natural protein (granulocyte-colony stimulating factor) produced by your own body. Ristempa is used to reduce the duration of neutropenia (low white blood cell count) and the occurrence of febrile neutropenia (low white blood cell count with a fever) which can be caused by the use of cytotoxic chemotherapy (medicines that destroy rapidly growing cells). White blood cells are important as they help your body fight infection. These cells are very sensitive to the effects of chemotherapy which can cause the number of these cells in your body to decrease. If white blood cells fall Lestu allt skjalið
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Ristempa 6 mg solution for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 6 mg of pegfilgrastim* in 0.6 ml solution for injection. The concentration is 10 mg/ml based on protein only**. *Produced in _Escherichia coli_ cells by recombinant DNA technology followed by conjugation with polyethylene glycol (PEG). ** The concentration is 20 mg/ml if the PEG moiety is included. The potency of this product should not be compared to the potency of another pegylated or non- pegylated protein of the same therapeutic class. For more information, see section 5.1 Excipient(s) with known effect: Each pre-filled syringe contains 30 mg sorbitol (E420) Each pre-filled syringe contains less than 1 mmol (23 mg) sodium (see section 4.4). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. _ _ Clear, colourless solution for injection. _ _ 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Ristempa therapy should be initiated and supervised by physicians experienced in oncology and/or haematology. Posology One 6 mg dose (a single pre-filled syringe) of Ristempa is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy. Medicinal product no longer authorised 3 Method of administration Ristempa is injected subcutaneously. The injections should be given into the thigh, abdomen or Lestu allt skjalið